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ABSTRACT 48 
Background: Numerous randomized trials have compared coronary artery 49 
bypass grafting (CABG) and percutaneous coronary intervention (PCI) for 50 
patients with multivessel (MVD) or left main (LM) coronary artery disease. No 51 
studies have been powered to detect a difference in mortality. 52 
Methods: We performed a collaborative individual patient-data, pooled analysis 53 
of 11 randomized clinical trials comparing CABG with PCI using stents, in which 54 
a Heart Team selected patients with estimated clinical equipoise between CABG 55 
and PCI; ERACI II (n=450), ARTS (n=1205), MASS II (n=408), SoS (n=988), 56 
SYNTAX (n=1800), PRECOMBAT (n=600), FREEDOM (n=1900), VA CARDS 57 
(n=198), BEST (n=880), NOBLE (n=1184) and EXCEL (n=1905). Mortality rates 58 
up to 5 years were estimated using Kaplan-Meier curves, with comparisons 59 
between PCI and CABG performed in a random-effects Cox proportional hazards 60 
model stratified by trial. Consistency of treatment effect was explored in 61 
subgroup analyses according to baseline clinical and anatomical characteristics.   62 
Findings: A total of 11,518 patients were randomly assigned to PCI (n=5753) or 63 
CABG (n=5765). Mean SYNTAX score was 26·0 ± 9·5, with 1798 patients (22·1%) 64 
having a SYNTAX score ≥33. Over a mean follow-up of 3·8 ± 1·4 years, 976 65 
deaths occurred. Five-year all-cause mortality was 11·2% (539 deaths) after PCI 66 
and 9·2% (437 deaths) after CABG (HR=1·20, 95% CI 1·06-1·37; P=0·0038). All-67 
cause mortality was significantly different in patients with MVD (PCI: 11·5% 68 
versus CABG: 8·9%; HR=1·28, 95% CI 1·09-1·49; P=0·0019) but not in patients 69 
with LM disease (PCI: 10·7% versus CABG: 10·5%; HR=1·07, 95% CI 0·87-1·33; 70 
P=0·52). In patients with MVD, mortality was significantly higher with PCI versus 71 
CABG in diabetics (15·5% versus 10·0%, P=0·0004) but not in non-diabetics 72 
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(8·7% versus 8·0%, P=0·49). Moreover, the difference between PCI and CABG in 73 
patients with MVD showed a stepwise increase from SYNTAX score 0-22 74 
(P=0·59) to 23-32 (P=0·0129) to ≥33 (P=0·0094). In patients with LM disease, 75 
comparable outcomes were not significantly influenced by the presence of 76 
diabetes or increasing SYNTAX scores. 77 
Interpretation: In this individual patient-data, pooled analysis of 11 78 
randomized trials in which a Heart Team selected patients, five-year mortality 79 
was significantly higher after PCI than CABG in patients with MVD, specifically in 80 
those with diabetes and higher coronary complexity. There were no significant 81 
differences in 5-year mortality between PCI and CABG in patients with LM 82 
disease, regardless of diabetes and SYNTAX score. Longer follow-up is needed to 83 
better define mortality differences.  84 
Keywords: Coronary artery bypass grafting; CABG; Percutaneous coronary 85 
intervention; PCI; Stenting; Left main; Multivessel; Survival; Mortality 86 
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INTRODUCTION 87 
Numerous randomized trials have compared coronary artery bypass grafting 88 
(CABG) and percutaneous coronary intervention (PCI) using either balloon 89 
angioplasty, bare-metal stents (BMS) or drug-eluting stents (DES) for the treatment 90 
of multivessel (MVD) or left main (LM) coronary artery disease.1-3 No individual trial 91 
has convincingly demonstrated a significant difference in all-cause mortality 92 
between the revascularization strategies. Hlatky and colleagues performed a pooled 93 
individual patient-data analysis of ten randomized trials including 7812 patients 94 
who underwent CABG with PCI using balloon angioplasty or BMS and reported five-95 
year mortality to be 8·4% after CABG and 10·0% after PCI (P=0·12).1 More 96 
contemporary trials comparing CABG versus PCI using DES have reported similar 97 
mortality rates. Despite the large number of clinical trials, all were underpowered to 98 
detect a difference in all-cause mortality. The objective of the present study was to 99 
overcome this limitation by pooling individual patient-data from all randomized 100 
trials comparing CABG with PCI using contemporary techniques (e.g. stents for PCI) 101 
to examine their comparative effects on long-term all-cause mortality in all patients, 102 
and separately in patients with MVD and LM disease. 103 
 104 
METHODS 105 
Reporting of this individual patient-data, pooled analysis concurs with specific 106 
PRISMA guidelines.4 This study is not registered and no protocol has been published. 107 
 108 
Study Selection and Data Collection 109 
A literature search of the MEDLINE, EMBASE, and Cochrane databases was 110 
performed on July 19, 2017 using the following keywords: “coronary artery bypass 111 
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grafting”, “percutaneous coronary intervention”, “stent”, and “random*”. Two 112 
researchers (SJH and MM) independently identified randomized trials comparing 113 
CABG and PCI with the following characteristics: (i) patients were randomly 114 
assigned to undergo CABG or PCI treatment, (ii) patients had multivessel and/or left 115 
main coronary artery disease, (iii) patients did not present with an acute myocardial 116 
infarction (MI); (iv) PCI was performed using stents (BMS or DES) and not balloon 117 
angioplasty, and (v) more than one-year follow-up for all-cause mortality was 118 
available (Appendix 1). Abstracts from meetings were not considered, nor were 119 
unpublished trials. Reference lists from potentially relevant literature were checked 120 
to ensure no studies were missed.  121 
From the 19 trials that were identified from the literature search, four trials were 122 
excluded because patients did not have multivessel or LM disease, one trial was 123 
excluded because only 54% of patients received a stent, and two trials were 124 
excluded because follow-up was only available up to one year (Appendix 1). 125 
Principal investigators of the remaining 12 trials were contacted to obtain individual 126 
patient data for a pooled analysis. One trial was unable to provide the data (n=105),5 127 
and investigators from the other 11 trials provided data in a standardized 128 
spreadsheet for the current pooled analysis: ERACI II6, ARTS7, MASS-II8, SoS9, 129 
SYNTAX10, PRECOMBAT11, FREEDOM12, VA CARDS (Cooperative studies program 130 
[CSP] study #557)13, BEST14, NOBLE15, and EXCEL16. Data were cross-checked 131 
against the publication of the primary endpoint and long-term follow-up 132 
publications. Several minor inconsistencies were resolved by contacting trial 133 
principal investigators. Baseline and procedural characteristics of individual trials 134 
are presented in the Appendix 2, with information of missing data for specific 135 
characteristics. Core laboratory assessed SYNTAX scores were available from 6 trials 136 
and a total of 8138 patients (CABG: n=4057, PCI: n=4081). 137 
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The quality of individual trials was assessed using the Cochrane Collaboration’s tool 138 
for assessing risk of bias.17 All trials were considered to have a high quality 139 
according to the criteria, despite not being able to blind investigators and patients 140 
(Appendix 3). 141 
Local Medical Ethics Committees approved each trial at the time of study execution, 142 
and all patients provided written informed consent. 143 
 144 
Outcomes and Follow-up 145 
To allow a consistent definition of follow-up time among trials, the duration of 146 
follow-up was calculated from the procedure. If patients died before the procedure, 147 
the time from randomization to death was used to calculate the duration of follow-148 
up. All-cause mortality was the primary endpoint of this study, with analyses 149 
planned in all patients, and separately in patients with MVD and LM disease. Planned 150 
analyses were also performed for trials using BMS, all DES, and for first-generation 151 
DES and newer-generation DES. First-generation DES were paclitaxel-eluting stents 152 
or sirolimus-eluting stents. Newer-generation DES were everolimus-eluting stents, 153 
zotarolimus-eluting stents, and biolimus-eluting stents. The VA CARDS trial was 154 
excluded from the separate analysis of first-generation and newer-generation DES, 155 
because a mix of first-generation and newer-generation DES was used. We 156 
furthermore pre-specified subgroup analyses according to the following baseline 157 
characteristics: sex, age, body mass index, hypertension, hyperlipidemia, diabetes 158 
mellitus, peripheral vascular disease, previous MI, left ventricular ejection fraction, 159 
and lesion complexity as defined by the SYNTAX score. Post-hoc subgroup analyses 160 
were performed according to SYNTAX score tertiles in the overall groups of patients 161 
with or without diabetes. 162 
In all trials, a Clinical Events Committee (CEC) adjudicated the events.  163 
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 164 
Statistical Analysis 165 
All analyses were performed according to intention-to-treat, with patients stratified 166 
according to the procedure assigned to by randomization. Individual patient 167 
baseline, procedural, and outcome data were pooled. Continuous variables were 168 
expressed as mean ± standard deviation and compared using t-tests, and discrete 169 
data were presented as frequencies and compared using chi-square tests. We pooled 170 
data from all 11 trials to provide unadjusted Kaplan-Meier estimates of all-cause 171 
mortality in overall and landmark analyses at 30 days, five years, and between 31 172 
days and five years. Comparisons between PCI and CABG were performed using Cox 173 
proportional hazards models stratified by trial, using a gamma frailty term to 174 
account for heterogeneity between trials. In this model, each trial is considered as an 175 
individual study and the random-effects model establishes a single hazard ratio 176 
(HR). Frailties are unobserved factors, distributed as γ random variables with a 177 
mean of 1 and variance ϑ. Hence, the variance of the frailty terms represents 178 
heterogeneity in baseline risk among trials. The statistical significance of the 179 
variance parameter was assessed using the likelihood ratio test. The proportionality 180 
assumption was tested for the overall analysis and was not violated (P=0·12). 181 
Nevertheless, visual inspection of the Kaplan-Meier curves suggests a time-182 
dependent variance in the HR of PCI versus CABG, and therefore time-dependent 183 
models were also performed. Subgroup analyses according to baseline clinical, 184 
procedural and anatomical characteristics were performed using the same Cox 185 
models. A two-sided P<0.05 was considered to indicate statistical significance; 186 
adjusting for multiplicity was not performed. All statistical analyses were performed 187 
using SPSS software version 21 (IBM Corporation, Armonk, NY, USA) or R software 188 
version 3.2.4 (Institute for Statistics and Mathematics of WU, Wien, Austria). 189 
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 190 
Role of Source Funding and Trial Sponsors 191 
This current study was performed without funding, although individual trials were 192 
sponsored (see the end of the manuscript). 193 
A team consisting of three epidemiologists and statisticians (M.M, E.B, and G.P) 194 
performed the statistical analyses. The decision to submit the manuscript for 195 
publication was made together by the principal investigators of the individual trials. 196 
Sponsors of the individual trials were involved with data collection in the individual 197 
trials, but uninvolved in performance of the analyses, interpretation of the data, or 198 
drafting of the manuscript.  199 
 200 
RESULTS 201 
Study Population and Procedures 202 
The 11 trials randomly assigned 11,518 patients to CABG (n=5765) or PCI (n=5753). 203 
Four trials were performed with BMS (n=3051), four trials with first-generation DES 204 
(n=4498), and three trials with newer-generation DES (n=3969). PCI was performed 205 
with BMS in 26·6%, with first-generation DES in 39·2%, and with newer-generation DES 206 
in 34·2% of patients (Table 1). Data from individual trials are presented in the Appendix 207 
2, including information on actual treatments performed (Appendix 4). 208 
Patients had a mean age of 63·6 ± 9·8 years and 23·8% were female (Table 1). Diabetes 209 
was present in 38·1% of patients, and 12·4% were on insulin treatment. Unstable 210 
angina was present in 34·4% of patients and 27·7% had a prior MI, although only 1·0% 211 
had a left ventricular ejection fraction <30%. Three-vessel disease was present in 60·2% 212 
of patients, and 38·9% had significant LM disease. The mean SYNTAX score was 26·0 ± 213 
9·5, with 1798 patients (22·1%) having a SYNTAX score ≥33. 214 
Surgery was performed with a left internal mammary artery in 96·2% of patients, with 215 
bilateral internal mammary arteries in 18·7%. Procedures were performed off-pump in 216 
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27·5% of patients. In 73·4% of patients DES were used during PCI, with 53·4% of those 217 
being first-generation DES and 46·6% being newer-generation DES. 218 
Patients were discharged with aspirin after CABG and PCI in 95·5% and 97·3%, 219 
respectively, and 44·0% and 95·1% with dual antiplatelet therapy, respectively 220 
(P<0·0001 for both analyses). Other secondary prevention was also higher at discharge 221 
after PCI than after CABG (Table 1). 222 
The mean duration of follow-up was 3·8 ± 1·4 years. 223 
 224 
Mortality in all patients 225 
A total of 976 deaths occurred during follow-up. Five-year all-cause mortality was 226 
11·2% (539 deaths) after PCI and 9·2% (437 deaths) after CABG (HR=1·20, 95% CI 227 
1·06-1·37; P=0·0038) (Figure 1; Table 2). At 30-day follow-up, mortality occurred in 76 228 
patients (1·3%) after PCI and in 78 patients (1·4%) after CABG (HR=0·97, 95% CI 0·71-229 
1·33; P=0·84). In a landmark analysis, mortality between 31 days and 5 years occurred 230 
in 463 patients (10·0%) following PCI and in 359 patients (8·0%) following CABG 231 
(HR=1·26, 95% CI 1·09-1·44; P=0·0009). A time-dependent model showed that the 232 
hazard of mortality was comparable between PCI and CABG during the first year of 233 
follow-up (HR=0∙97, 95% CI 0∙80-1∙19; P=0.80), but was in favour of CABG beyond one-234 
year follow-up (HR=1·39, 95% CI 1·17-1·62; P<0·0001)(Appendix 5). The estimate of 235 
the frailty parameter for heterogeneity was significant (θ=0·39, P<0·0001). 236 
Patients randomized in trials in which DES were used were significantly older, had more 237 
comorbidities, and more complex coronary disease than patients randomized in trials in 238 
which BMS were used (Table 3). Particularly, in DES versus BMS trials, diabetes was 239 
present in 45·4% versus 17·8%, respectively, LM disease was present in 52·5% versus 240 
1·0%, respectively, and three-vessel disease in 70·6% versus 41·9% (P<0·0001 for all). 241 
Five-year mortality in BMS trials (n=3051) was 8·7% (131 deaths) after PCI and 8·2% 242 
(125 deaths) after CABG (HR=1·05, 95% CI 0·82-1·34; P=0·72). In DES trials (n=8467), 243 
10 
 
5-year mortality was 12·4% (408 deaths) after PCI with DES and 10·0% (312 deaths) 244 
after CABG (HR=1·27, 95% CI 1·09-1·47; P=0·0022). The interaction for CABG versus 245 
PCI with BMS or DES was not significant (P for interaction = 0·53). Although there were 246 
significant differences in clinical and anatomical characteristics between trials using 247 
first-generation DES and those using newer-generation DES (Table 3), the difference in 248 
5-year mortality between PCI and CABG was consistent when analyzing the 4300 249 
patients enrolled in trials using first-generation DES (PCI: 13·2% (254 deaths) versus 250 
CABG: 11·1% (201 deaths); P=0·0391) and the 3969 patients enrolled in trials using 251 
newer-generation DES (PCI: 10·3% (136 deaths) versus CABG: 7·9% (106 deaths); 252 
P=0·0684) (P for interaction = 0·78). 253 
In subgroup analyses, the difference in mortality was consistent according to most 254 
baseline characteristics (Figure 2; Table 2). Diabetes was the only baseline 255 
characteristic for which a significant treatment interaction was present (P for 256 
interaction = 0·0077). In patients with diabetes there was a higher mortality with PCI 257 
compared with CABG (15·7% versus 10·7%, respectively; HR=1·44, 95% CI 1·20-1·74; 258 
P=0·0001), whereas mortality was comparable in patients without diabetes (PCI 8·7% 259 
versus CABG 8·4%; HR=1·02, 95% CI 0·86-1·21; P=0·81) (Figures 2 and 3B). Of note, 260 
although the interaction was not significant, the mortality benefit of CABG over PCI 261 
tended to be progressively greater with increasing SYNTAX scores (Table 2). Similar 262 
trends were found in subgroups of patients with or without diabetes (Appendix 6). 263 
 264 
Multivessel disease 265 
Among patients with multivessel disease randomized to PCI (n=3520) versus CABG 266 
(n=3520), there were 644 deaths during a mean of 4·1 ± 1·4 years follow-up. The 5-year 267 
rate of all-cause mortality was higher after PCI: 11·5% (365 deaths) versus 8·9% (279 268 
deaths) after CABG (HR=1·28, 95% CI 1·09-1·49; P=0·0019) (Figure 3D; Table 2). 269 
Results of time-dependent models are provided in the Appendix 5; similar as for the 270 
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overall patient cohort, the benefit of CABG in MVD was particularly present with longer 271 
follow-up. 272 
In patients with multivessel disease, mortality was 15·5% after PCI versus 10·0% after 273 
CABG, in the 3266 patients with diabetes (HR=1·48, 95% CI 1·19-1·84; P=0·0004), and 274 
8·7% after PCI versus 8·0% after CABG, in the 3774 patients without diabetes (HR=1·08, 275 
95% 0·86-1·36; P=0·49) (P for interaction = 0·0453) (Table 2). 276 
The mortality benefit of CABG over PCI was greater with increasing SYNTAX scores in 277 
patients with multivessel disease. The respective mortality rates after PCI and CABG 278 
were 10·5% versus 8·4% in 1381 patients with a SYNTAX score of 0-22 (HR=1·11, 95% 279 
CI 0·77-1·62, P=0·57), 14·0% versus 9·5% in 1599 patients with a SYNTAX score of 23-280 
32 (HR=1·50, 95% CI 1·09-2·08; P=0·0129), and 19·2% versus 11·2% in 820 patients 281 
with a SYNTAX score of ≥33 (HR=1·70, 95% CI 1·13-2·55; P=0·0094) (P for interaction = 282 
0·32) (Table 2). 283 
 284 
Left main disease 285 
Among patients with LM disease randomized to PCI (n=2233) versus CABG (n=2245), 286 
there were 322 deaths during a mean of 3·4 ± 1·4 years follow-up. The 5-year rate of all-287 
cause mortality was comparable with 10·7% (174 deaths) after PCI and 10·5% (158 288 
deaths) after CABG (HR=1·07, 95% CI 0·87-1·33; P=0·52) (Figure 3C; Table 2). Results 289 
of time-dependent models are provided in the Appendix 5; in contrast to the overall 290 
cohort and MVD subgroup, the benefit of CABG was not seen with longer follow-up. 291 
In subgroup analysis according to diabetes in patients with LM disease, there was no 292 
significant interaction in the treatment effect (P for interaction = 0·13). In 1120 patients 293 
with diabetes mortality was 16·5% after PCI versus 13·4% after CABG (HR=1·34, 95% 294 
CI 0·93-1·91; P=0·11) and 8·8% after PCI versus 9·6% after CABG in 3358 patients 295 
without diabetes (HR=0·94, 95% CI 0·72-1·23; P=0·65) (Table 2). 296 
12 
 
Analyses according to SYNTAX score in patients with LM disease revealed that there 297 
were no differences in mortality among PCI and CABG in any of the groups: 8·1% versus 298 
8·3% among 1737 patients with a SYNTAX score of 0-22 (HR=0·91, 95% CI 0·60-1·36, 299 
P=0·64), 10·8% versus 12·7% among 1623 patients with a SYNTAX score of 23-32 300 
(HR=0·92, 95% CI 0·65-1·30; P=0·65), and 15·0% versus 12·4% among 978 patients 301 
with a SYNTAX score of ≥33 (HR=1·39, 95% CI 0·94-2·06; P=0·1006) (P for interaction = 302 
0·38) (Table 2).  303 
 304 
DISCUSSION 305 
This collaborative analysis of individual patient data from 11 randomized trials is the 306 
first large-scale analysis of data comparing CABG and PCI performed using stents. In a 307 
total of 11,518 randomly assigned patients, the 5-year mortality rate was significantly 308 
higher after PCI than after CABG. However, this difference was not consistent among 309 
subgroups. Specifically, the mortality benefit of CABG over PCI was seen only in patients 310 
with multivessel disease and diabetes. Conversely, there were no significant differences 311 
in mortality between CABG and PCI in patients without diabetes who had multivessel 312 
disease, or in all patients with left main disease (with or without diabetes). Coronary 313 
lesion complexity was an important effect modifier, particularly in patients with 314 
multivessel disease. 315 
The difference between CABG and PCI using stents is a topic of debate that is fueled each 316 
time stent design is enhanced. Due to these improvements, randomized trials comparing 317 
CABG and PCI have increasingly included higher-risk patients with more complex 318 
disease, such as three-vessel or left main disease. This is also reflected in our data 319 
wherein 5-year all-cause mortality in both the CABG and PCI cohorts was higher in 320 
contemporary trials with DES versus earlier trials in which BMS were used.  321 
It is important to acknowledge that in these trials, both an interventional cardiologist 322 
and a cardiac surgeon had to assume clinical equipoise between PCI and CABG for 323 
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patients to be randomized. Such a Heart Team concept has received more emphasis over 324 
the recent years to determine the best revascularization strategy for individual 325 
patients.18 Some patients were not eligible for inclusion in the selected randomized 326 
trials due to coronary lesion complexity too severe to be treated by PCI or an operative 327 
risk deemed to high to undergo CABG.19 The results of this analysis therefore do not 328 
correspond to the entire population of patients with coronary artery disease that 329 
require revascularization. 330 
The mortality benefit of CABG versus PCI in the overall group was retained over a 331 
variety of patient baseline characteristics. However, the presence of diabetes remained 332 
as an important factor, as demonstrated in previous analyses.1 The benefit of CABG in 333 
patients with diabetes may be attributed to more effective revascularization of diffuse, 334 
complex coronary disease. This is consistent with the findings of the subgroup analyses 335 
according to SYNTAX score. In the total cohort, there was a step-wise increase in the 336 
difference between CABG and PCI with higher SYNTAX scores. Other studies have 337 
identified sex as an effect modifier,20 but we were unable to confirm a significant 338 
treatment-by-sex interaction for 5-year mortality. 339 
Patients with multivessel disease have lower mortality with CABG, as shown in the 340 
SYNTAX trial that compared CABG with PCI with first-generation DES.21,22 The BEST trial 341 
in which second-generation, everolimus-eluting stents were used to treat multivessel 342 
disease also found that CABG was associated with lower rates of major adverse cardiac 343 
or cerebrovascular events, driven by a reduced rate of MI and repeat 344 
revascularization.14 However, both trials failed to show a survival benefit for either 345 
treatment. Large real-world registries that applied propensity matching of CABG versus 346 
PCI with DES for multivessel disease have attempted to find such differences with larger 347 
sample sizes.23,24 The ASCERT study, the largest such analysis, reported an adjusted 4-348 
year mortality of 16.4% for CABG and 20.8% for PCI among a cohort of patients aged 65 349 
years or older, which was consistent in multiple subgroups.24 Notably, a similar pattern 350 
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of the survival curves of CABG versus PCI is observed when comparing those of the real-351 
world ASCERT study in which patients were treated with first-generation DES and that 352 
of the current analysis: PCI shows a benefit within the first year of follow-up but with 353 
longer follow-up there is a larger benefit with CABG. We were able to show that this 354 
reversal of the hazard resulted in a significant benefit of CABG over PCI at a mean of 4·1 355 
years, which may potentially become larger with prolonged follow-up as the hazard 356 
ratio was more in favour of CABG at later follow-up in time-varying models.  357 
Among patients with LM disease randomized in the SYNTAX trial, comparable 5-year 358 
mortality between CABG and paclitaxel-eluting, first-generation DES was noted.25 Two 359 
major trials have since focused on finding the optimal revascularization strategy for LM 360 
disease and have recently reported conflicting outcomes of CABG versus PCI. The EXCEL 361 
trial reported non-inferiority of PCI versus CABG after 3 years, while the NOBLE trial did 362 
not demonstrate non-inferiority of PCI versus CABG at 5 years.15,16 The differences in 363 
timing and composition of the primary endpoints make a comparison of these trials 364 
difficult and can presumably explain the apparent difference in results. Three-year 365 
individual endpoints in the NOBLE trial were later confirmed to be remarkably similar 366 
to EXCEL.26 In the current pooled analysis of data from 4 different trials, mortality in 367 
patients with LM disease was similar after CABG and PCI at 5-year follow-up. The 368 
mortality comparison was consistent in a subgroup analysis according to diabetes, 369 
unlike the analysis of all patients and those with multivessel disease, although this may 370 
be due to smaller sample size in the diabetic subgroup of LM patients. Coronary 371 
complexity by SYNTAX score did not show to impact the mortality comparison, although 372 
patients with a high SYNTAX score were relatively underrepresented due to specific 373 
inclusion criteria (e.g. in the EXCEL trial) and a Heart Team preference for CABG.19 374 
Therefore, the degree of complexity should still be important to consider when 375 
proposing a specific treatment for individual patients with LM disease. Patients with a 376 
complex LM lesion and additional three-vessel disease with a high SYNTAX score may 377 
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still benefit from CABG in terms of mortality, as well as MI and repeat revascularization, 378 
while patients with a non-complex LM lesion and one or two-vessel disease may be 379 
excellent candidates for PCI. Clinical guidelines have not been revised since the release 380 
of the EXCEL and NOBLE trial data. Based on the current data of comparable mortality, 381 
the indication for PCI with contemporary DES may be broadened to patients with more 382 
complex LM disease (e.g. intermediate SYNTAX scores). However, since only 978 383 
patients in the present LM cohort had high SYNTAX scores, additional data is required 384 
before PCI can be routinely recommended in patients with complex LM disease. Longer 385 
follow-up is essential to better define differences in survival between CABG and PCI, as 386 
landmark analyses from the EXCEL trial showed that the hazard of mortality after CABG 387 
and PCI was different according to the period of follow-up and may show a benefit of 388 
CABG with longer follow-up.16  389 
The major strength of the current analysis is that we were able to find clinically relevant 390 
differences in all-cause mortality between CABG and PCI due to the collaboration of the 391 
principal investigators from 11 high-quality randomized trials, allowing pooled data to 392 
provide sufficient power to examine an outcome that occurs relatively infrequently. 393 
Indeed, all-cause mortality is considered to be the most clinically important and least 394 
biased endpoint, which is another strength of this analysis. Having individual patient 395 
data also facilitated formation of Kaplan-Meier curves so the temporal relationships of 396 
mortality could be examined, and analysis of outcomes in important subgroups, which 397 
in the present study were highly informative.   398 
Nevertheless, several limitations should also be considered. First, all the included trials 399 
randomized patients with estimated clinical equipoise between CABG and PCI. These 400 
trials had specific inclusion and exclusion criteria, and many patients were excluded 401 
because CABG or PCI was thought to be the preferred revascularization strategy based 402 
on the age, risk profile, or coronary complexity.19 This resulted in a population with only 403 
22·1% having a SYNTAX score ≥33. Second, these inclusion and exclusion criteria have 404 
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resulted in significant variance in the baseline characteristics of the patients from 405 
different trials, as shown by our assessment of frailty. Third, besides mortality, other 406 
outcome measures that impact morbidity and quality of life, such as MI, stroke, and 407 
repeat revascularization, are also important for the patient and should be taken into 408 
account by the Heart Team when deciding on the best revascularization option for each 409 
individual patient. In the current era of exponentially growing health care costs and the 410 
need to reduce expenses, the cost-effectiveness of PCI and CABG should furthermore be 411 
evaluated. Fourth, the mean patient age was 63.6 years, and the mean follow-up was 3·8 412 
years. Considering the life expectancy of patients, this follow-up is still relatively short 413 
to determine the full impact of revascularization method on survival, especially 414 
considering the diverging or converging Kaplan-Meier curves in specific subgroups. 415 
Fifth, definitions of patient characteristics may have slightly differed between trials, 416 
which may have impacted the results of the subgroup analyses. Sixth, we were unable to 417 
include data from the LE MANS trial5, although it is very unlikely that inclusion of these 418 
105 patients with LM disease would significantly alter the results, and thus the 419 
outcomes of this study are robust with respect to the available evidence. 420 
 421 
CONCLUSIONS 422 
In this individual patient-data, pooled analysis from 11 trials in which a Heart Team 423 
randomized 11,518 patients with estimated clinical equipoise between PCI and CABG, 5-424 
year mortality was significantly lower after CABG as compared with PCI. The benefit 425 
was demonstrated only in patients with multivessel disease and diabetes, but not in 426 
patients with multivessel disease without diabetes. Nor was there a benefit of CABG or 427 
PCI in patients with LM disease. Coronary lesion complexity is an important factor to 428 
consider when choosing the appropriate revascularization strategy, especially in 429 
patients with multivessel disease. Longer follow-up is needed to better define mortality 430 
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differences. These results may not be applicable to patients excluded from randomized 431 
trials for various reasons (e.g. coronary complexity or procedural risk).  432 
 433 
RESEARCH IN CONTEXT 434 
Evidence before this study 435 
A literature search of the MEDLINE, EMBASE, and Cochrane databases was performed 436 
on July 19, 2017 to identify randomized clinical trials comparing coronary artery bypass 437 
grafting and percutaneous coronary intervention with stents using the following 438 
keywords: “coronary artery bypass grafting”, “percutaneous coronary intervention”, 439 
“stent”, and “random*”, with the following characteristics: (i) patients had multivessel 440 
and/or left main coronary artery disease, (ii) patients did not present with an acute 441 
myocardial infarction (MI); (iii) PCI was performed using stents (BMS or DES) and not 442 
balloon angioplasty, and (iv) more than one-year follow-up for all-cause mortality was 443 
available. We identified 12 high-quality trials, none of which found a significant 444 
difference in all-cause mortality between PCI and CABG at 3-10 year follow-up. Separate 445 
meta-analyses of randomized clinical trials that included patients with multivessel 446 
disease or with left main disease showed no significant differences in all-cause mortality 447 
between PCI and CABG. Meta-analyses did show that patients with diabetes have a 448 
benefit with CABG over PCI as opposed to patients without diabetes where no difference 449 
was found, although this has been contradicted in other pooled analyses.  450 
Added value of this study 451 
This study is the largest analysis of patients randomly assigned to PCI with stents or 452 
CABG. It shows for the first time, to the best of our knowledge, that all-cause mortality is 453 
significantly lower with CABG than with PCI in an overall randomized population of 454 
patients with multivessel or left main disease. However, because of the use of individual 455 
patient data, important subgroups are identified that have a survival benefit from CABG, 456 
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which are patients with multivessel disease and diabetes, and high coronary lesion 457 
complexity. Patients with left main disease and lower coronary lesion complexity have 458 
comparable survival with PCI and CABG. 459 
Implications of all the available evidence 460 
Some patients have specific indications for PCI or CABG because of too high coronary 461 
complexity for PCI or too high operative risk for CABG. In patients with estimated 462 
clinical equipoise as determined by a Heart Team, it is crucial to consider the presence 463 
of multivessel or left main disease, the coronary complexity as determined by the 464 
SYNTAX score, and the presence of diabetes, as these are important effect modifiers in 465 
terms of PCI versus CABG and should impact the decisions for coronary 466 
revascularization in daily practice. However, longer follow-up of randomized trials is 467 
required to better define mortality differences in overall patients and specific 468 
subgroups.469 
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TABLES 
Table 1. Baseline, procedural, and discharge data of randomized cohorts. 
Characteristic PCI (n=5753) CABG (n=5765) P value 
Age 
 
63·6 ± 9·8 (5753) 63·7 ± 9·9 (5765) 0·72 
Female sex 23·9% (1373/5753) 23·8% (1371/5765) 0·91 
BMI >30 kg/m2 
 
28·1% (1548/5506) 28·3% (1558/5511) 0·82 
Smoking current 22·3% (1274/5701) 22·3% (1273/5703) 0·97 
Diabetes 
 
38·5% (2215/5753) 37·7% (2171/5765) 0·35 
 Insulin treated 12·9% (545/4234) 11·9% (504/4245) 0·16 
Hypertension 67·6% (3880/5739) 68·1% (3913/5748) 0·59 
Hypercholesterolemia 69·5% (3982/5726) 67·3% (3862/5735) 0·0112 
Peripheral vascular disease 8·2% (424/5158) 8·5% (440/5164) 0·58 
Carotid artery disease 7·8% (161/2072) 8·1% (168/2074) 0·69 
Previous TIA or CVA 5·4% (218/4052) 6·2% (253/4054) 0·0977 
Previous MI 28·0% (1438/5138) 27·5% (1417/5156) 0·57 
Moderate LVEF (30-49%) 15·2% (807/5303) 14·3% (779/5430) 0·20 
Poor LVEF (<30%) 0·9% (49/5303) 1·0 (54/5430) 0·71 
Unstable angina pectoris 34·6% (1786/5158) 34·2% (1767/5160) 0·68 
Three-vessel disease 58·6% (2460/4201) 61·8% (2594/4197) 0·0627 
Left main disease 38·8% (2233/5753) 38·9% (2245/5765) 0·89 
SYNTAX score 26·0 ± 9·3 (4081) 26·0 ± 9·8 (4057) 0·91 
 0-22 37·6 (1533/4081) 39·1 (1585/4057) 0·16 
 23-32 41·1 (1677/4081) 38·1 (1545/4057) 0·0053 
 ≥33 21·3 (871/4081) 22·8 (927/4057) 0·10 
PCI – stents* 100% (5610/5610) - - 
 BMS 26·6% (1490/5610) - - 
 DES 73·4% (4120/5610) - - 
  First-generation DES 39·2% (2199/5610) - - 
  Newer-generation DES 34·2% (1920/5610) - - 
PCI – number of stents 3·1 ± 2·0 (4935) - - 
CABG – LIMA use - 96·2% (4574/4753) - 
CABG – BIMA use - 18·7% (771/4122) - 
CABG – off-pump - 27·5% (1085/3945) - 
Aspirin at discharge 97·3% (4487/4612) 95·5% (3814/3994) <0·0001 
Thienopyridine at discharge 96·7% (4479/4630) 45·1% (1815/4026) <0·0001 
DAPT at discharge 95·1% (4384/4612) 44·0% (1759/3994) <0·0001 
Statin at discharge 88·1% (3052/3464) 84·0% (2843/3384) <0.0001 
Beta-blocker at discharge 79·1% (2741/3464) 76·2% (2557/3356) 0.0040 
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ACEi or ARB at discharge 63·7% (2205/3464) 46·9% (1588/3383) <0·0001 
Calcium-channel blocker at 
discharge 
27·7% (959/3463) 21·8% (736/3383) <0·0001 
*Data only for patients who were randomized to PCI and indeed underwent PCI. The type of DES used was 
not available for one patient enrolled in the VA CARDS trial.  
Values are present as mean ± SD or n/N (%). PCI, percutaneous coronary intervention; CABG, coronary 
artery bypass grafting; ACEi, angiotensin-converting enzyme inhibitor; ARD, angiotensin II receptor 
blocker; BMI, body mass index; BMS = bare-metal stent; TIA, transitory ischemic attack; CVA, 
cerebrovascular attack; MI, myocardial infarction; LVEF, left ventricular ejection fraction; DES, drug-
eluting stents; LIMA, left internal mammary artery; BIMA, bilateral internal mammary artery; DAPT, dual 
antiplatelet therapy.  
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Table 2. Five-year mortality outcomes in all patients and according to multivessel or left main disease  
  All patients  Multivessel disease  Left main disease  
CABG 
(n=5765) 
PCI  
(n=5753) 
HR [95% CI] 
P value 
Heteroge
neity 
CABG 
(n=3520) 
PCI 
(n=3520) 
HR [95% CI] 
P value 
Heteroge
neity 
CABG 
(n=2245) 
PCI 
(n=2233) 
HR [95% CI] 
P value 
Heteroge
neity 
Overall 
mortality 
9·2% 
(437/576
5) 
11·2% 
(539/5753) 
HR=1·20 
[1·06-1·37] 
P=0·0038 
ϑ=0·39 
P<0·0001 
8·9% 
(279/3520) 
11·5% 
(365/3520) 
HR=1·28 
[1·09-1·49] 
P=0·0019 
ϑ=0·40 
P<0·0001 
10·5% 
(158/224
5) 
10·7% 
(174/2233) 
HR=1·07 
[0·87-1·33] 
P=0·52 
ϑ=0·0845 
P<0·0001 
Diabetes   Pint 0·008    Pint 0·0453    Pint 0·13  
 Yes 10·7% 
(185/217
1) 
15·7% 
(278/2215) 
HR=1·44 
[1·20-1·74]  
P=0·0001 
ϑ=0·11 
P<0·0001 
10·0% 
(134/1622) 
15·5% 
(207/1644) 
HR=1·48 
[1·19-1·84] 
P=0·0004 
ϑ=0·16 
P<0·0001 
13·4% 
(51/549) 
16·5% 
(71/571) 
HR=1·34 
[0·93-1·91] 
P=0·11 
ϑ=0·0536 
P=0·0177 
 No 8·4% 
(252/359
4) 
8·7% 
(261/3538) 
HR=1·02 
[0·86-1·21] 
P=0·81 
ϑ=0·0884 
P<0·0001 
8·0% 
(145/1898) 
8·7% 
(158/1876) 
HR=1·08 
[0·86-1·36] 
P=0·49 
ϑ=0·0992 
P<0·0001 
9·6% 
(107/169
6) 
8·8% 
(103/1662) 
HR=0·94 
[0·72-1·23] 
P=0·65 
ϑ=0·0603 
P=0·0027 
SYNTAX 
score 
  Pint 0·21    Pint 0·32    Pint 0·38  
 0-22 8·1% 
(100/158
5) 
8·8% 
(105/1533) 
HR=1.02 
[0.77-1.34] 
P=0.91 
ϑ=0·0459 
P=0·0092 
8·4% 
(51/691) 
10·5% 
(60/690) 
HR=1·11 
[0·77-1·62] 
P=0·57 
ϑ=0·0523 
P=0·0131 
8·3% 
(49/894) 
8·1% 
(45/843) 
HR=0·91 
[0·60-1·36] 
P=0·64 
ϑ<0·0001 
P=0·0001 
 23-32 10·9% 
(122/154
5) 
12·4% 
(163/1677) 
HR=1.20 
[0.94-1.51] 
P=0.14 
ϑ=0·0656 
P=0·0031 
9·5% 
(59/775) 
14·0% 
(96/824) 
HR=1·50 
[1·09-2·08] 
P=0·0129 
0·0621 
P=0·0066 
12·7% 
(63/770) 
10·8% 
(67/853) 
HR=0·92 
[0·65-1·30] 
P=0·65 
ϑ=0·0626 
P=0·0093 
 ≥33 11·6% 
(83/9276) 
16·5% 
(117/871) 
HR=1.52 
[1.15-2.02] 
P=0.0029 
ϑ=0·0189 
P=0·0609 
10·9% 
(38/423) 
17·7% 
(61/397) 
HR=1·70 
[1·13-2·55] 
P=0·0094 
ϑ=0·0252 
P=0·0504 
12·4% 
(45/504) 
15·0% 
(56/474) 
HR=1·39 
[0·94-2·06] 
P=0·1006 
ϑ=0·0217 
P=0·0652 
Percentages are from unadjusted Kaplan-Meier estimates; the number of events is provided between brackets. Hazard ratios with confidence intervals and p-values 
are from random-effects Cox proportional hazards models stratified by trial. CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention; Pint= P 
for interaction 
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Table 3. Differences in patient characteristics among BMS and DES trials. 
Characteristic BMS  
(n=3051) 
All DES  
(n=8467) 
P-Value First-generation DES  
(n=4300) 
Newer-generation DES 
 (n=3969) 
P-Value 
Age  60·8 ± 10·1 (3051) 64·7 ± 9·6 (8467) <0·0001 63·8 ± 9·5 (4300) 65·7 ± 9·6 (3969) <0·0001 
Female sex 23·2% (707/3051) 24·1% (2037/8467) 0·32 25·3% (1087/4300) 23·9% (948/3969) 0·14 
BMI >30 kg/m2  22·3% (578/2593) 30·0% (8424/2528) <0·0001 32·4% (1388/4290) 25·6% (1010/3939) <0·0001 
Smoking current 27·5% (843/3049) 20·4% (1704/8355) <0·0001 19·6% (833/4260) 21·2% (827/3900) 0·0642 
Diabetes  17·8% (543/3051) 45·4% (3843/8467) <0·0001 59·2% (2544/4300) 27·7% (1101/3969) <0·0001 
 Insulin treated 3·4% (48/1396) 14·1% (1001/7083) <0·0001 19·0% (816/4299) 6·6% (185/2784) <0·0001 
Hypertension 51·1% (1558/3051) 73·9% (6235/8436) <0·0001 76·5% (3278/4287) 70·1% (2770/3954) <0·0001 
Hypercholesterolemia 58·3% (1776/3047) 72·1% (6068/8414) <0·0001 75·4% (3230/4285) 69·2% (2727/3938) <0·0001 
Peripheral vascular disease 7·6% (233) 8·7% (631/7271) 0·0813 9·2% (396/4300) 7·5% (208/2776) 0·0116 
Carotid artery disease 5·6% (25/450) 8·2% (304/3696) 0·0479 8·2% (148/1800) 8·2% (156/1896) 0·99 
Previous TIA or CVA 3·3% (47/1438) 6·4% (424/6668) <0·0001 5·8% (215/3688) 6·8% (189/2782) 0·11 
Previous MI 42·1% (1285/1766) 21·7% (1570/7243) <0·0001 25·8% (1105/4280) 13·9% (384/2768) <0·0001 
Moderate LVEF (30-49%) 16·1% (442/2746) 14·3% (1144/7987) 0.0239 15·7% (668/4242) 11·9% (425/3568) <0·0001 
Poor LVEF (<30%) 0·1% (4/2746) 1·2% (99/7987) <0·0001 1·6% (66/4242) 0·6% (21/3568) <0·0001 
Unstable angina pectoris 41·2% (850/2063) 32·7% (2703/8255) <0·0001 31·8% (1369/4287) 33·7% (1334/3955) 0·0672 
Three-vessel disease 41·9% (1280/3051) 70·6% (3774/5348) <0·0001 69·4% (2976/4287) 77·2% (679/3969) <0·0001 
Left main disease 1·0% (29/3051) 52·5% (4449/8467) <0·0001 30·5% (1313/4300) 79·0% (3136/3969) <0·0001 
Mean follow-up (years) 4·7 ± 1·0 (2795) 3·5 ± 1·4 (7726) <0·0001 4·0 ± 1·4 (3830) 3·1 ± 1·2 (3723) <0·0001 
BMI, body mass index; BMS, bare-metal stents; TIA, transitory ischemic attack; CVA, cerebrovascular attack; MI, myocardial infarction; LVEF, left ventricular 
ejection fraction; DES, drug-eluting stents 
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FIGURE LEGENDS 
Figure 1. Mortality after coronary artery bypass grafting versus percutaneous 
coronary intervention during 5-year of follow-up. Kaplan-Meier estimates are from 
the overall pooled patient population. The hazard ratio (HR) with confidence intervals is 
derived from a Cox proportional hazards random-effects model stratified by trial. CABG, 
coronary artery bypass grafting; PCI, percutaneous coronary intervention. 
 
Figure 2. Mortality after coronary artery bypass grafting versus percutaneous 
coronary intervention during 5-year follow-up in subgroup analyses according to 
baseline and procedural characteristics. Kaplan-Meier estimates are from the overall 
pooled patient population. Hazard ratios (HRs) with confidence intervals (CIs) are 
derived from Cox proportional hazards random-effects models stratified by trial. HR, 
hazard ratio; CI, confidence interval. 
 
Figure 3. Mortality after coronary artery bypass grafting versus percutaneous 
coronary intervention during 5-year follow-up of patients with and without 
diabetes mellitus (A and B), and with left main or multivessel disease (C and D). 
Kaplan-Meier estimates are from the overall pooled patient population. Hazard ratios 
(HRs) with confidence intervals (CIs) are derived from Cox proportional hazards 
random-effects models stratified by trial. CABG, coronary artery bypass grafting; DM, 
diabetes mellitus; LM, left main disease; MVD, multivessel disease; PCI, percutaneous 
coronary intervention. 
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FIGURES 
 
Figure 1. Mortality after coronary artery bypass grafting versus percutaneous coronary 
intervention during 5-year of follow-up. Kaplan-Meier estimates are from the overall pooled patient 
population. The hazard ratio (HR) with confidence intervals is derived from a Cox proportional hazards 
random-effects model stratified by trial. CABG, coronary artery bypass grafting; PCI, percutaneous 
coronary intervention.  
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Figure 2. Mortality after coronary artery bypass grafting versus percutaneous coronary 
intervention during 5-year follow-up in subgroup analyses according to baseline and 
procedural characteristics. Kaplan-Meier estimates are from the overall pooled patient 
population. Hazard ratios (HRs) with confidence intervals (CIs) are derived from Cox 
proportional hazards random-effects models stratified by trial. HR, hazard ratio; CI, confidence 
interval.
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Figure 3. Mortality after coronary artery bypass grafting versus percutaneous coronary 
intervention during 5-year follow-up of patients with and without diabetes mellitus (A and 
B), and with left main or multivessel disease (C and D). Kaplan-Meier estimates are from the 
overall pooled patient population. Hazard ratios (HRs) with confidence intervals (CIs) are 
derived from Cox proportional hazards random-effects models stratified by trial. CABG, coronary 
artery bypass grafting; DM, diabetes mellitus; LM, left main disease; MVD, multivessel disease; 
PCI, percutaneous coronary intervention. 
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APPENDICES 
APPENDIX 1. Study selection flow-chart
Included trials (n=11) 
- ERACI II (n=450) 
- ARTS (n=1205) 
- MASS-II (n=408) 
- SoS (n=988) 
- SYNTAX (n=1800) 
- PRECOMBAT (n=600) 
- FREEDOM (n=1900) 
- VA CARDS (n=198) 
- BEST (n=880) 
- NOBLE (n=1184) 
- EXCEL (n=1905) 
 
Search on July 19, 2017, using keywords “coronary 
artery bypass”, “percutaneous coronary intervention”, 
“stent”, and “random*”  
MEDLINE 
(n=823) 
Cochrane 
(n=315) 
EMBASE 
(n=709) 
Investigators 
contacted (n=12 trials) 
Excluded trials (n=7) 
- Non-LM SVD: SIMA trial1, Diegeler et 
al3, Thiele et al4, Drenth et al5, and Hong 
et al6 
- No 100% stent use: AWESOME trial7 
- Only 1-year follow-up: Boudriot et al8, 
and CARDia trial9 
 
Excluded trial (n=1) 
- Unable to provide data: LE MANS 
trial2 
19 trials 
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APPENDIX 2. Baseline and procedural characteristics in individual trials. 
Characteristic ERACI II  
(n=450) 
ARTS  
(n=1205) 
MASS-II  
(n=408) 
SoS  
(n=988) 
SYNTAX  
(n=1800) 
PRECOMB
AT 
(n=600) 
FREEDOM 
(n=1900) 
VA CARDS 
(n=198) 
BEST  
(n=880) 
NOBLE  
(n=1184) 
EXCEL 
(n=1905) 
Patient inclusion 1996-1998 1997-1998 1995-2000 1996-1999 2005-2007 2004-2009 2005-2010 2006-2010 2008-2013 2008-2015 2010-2014 
Study location Argentina Europe, 
South 
America, 
Australasia 
Brazil Europe, 
Canada 
Europe, US Korea North 
America, 
South 
America, 
Europe, India, 
Australasia 
US Asia Europe North 
America, 
South 
America, 
Europe, 
India, 
Australasia 
Heart team 
composition 
“Clinical 
cardiologist, 
interventionalist, 
cardiac surgeon” 
“Intervention
al 
cardiologist 
and cardiac 
surgeon” 
“Inter-
ventionalist 
and 
surgeon” 
“Inter-
ventionalist 
and 
surgeon” 
“Interventional 
cardiologist 
and cardiac 
surgeon” 
“Physicians 
and 
surgeons” 
Not explicitly 
reported 
“Inter-
ventional 
cardiologist 
and cardio-
thoracic 
surgeon” 
“Physicians 
and 
surgeons” 
“Inter-
ventional 
cardiologist 
and cardiac 
surgeon” 
“Inter-
ventional 
cardiologist 
and cardiac 
surgeon” 
Age 60·7 ± 10·2 60·6 ± 10·8 59·8 ± 9·0 61·4 ± 9·3 65·1 ± 9·7 62·2 ± 9·7 62·1 ± 9·1 62·4 ± 7·2 64·5 ± 9·4 66·2 ± 9·7 65·9 ± 9·6 
Female sex 21% (93/450) 23% 
(283/1205) 
31% 
(125/408) 
21% 
(206/988) 
22% 
(402/1800) 
24% 
(141/600) 
29% 
(544/1900) 
1% 
(2/198) 
29% 
(251/880) 
22% 
(256/1184) 
23% 
(441/1905) 
BMI >30 kg/m2 NA 22% 
(260/1203) 
25% 
(100/408) 
22% 
(220/982) 
32% 
(579/1799) 
3% 
(20/595) 
42% 
(789/1896) 
68% 
(132/195) 
4% 
(35/880) 
29% 
(336/1155) 
34% 
(639/1904) 
Smoking current 52% (233/540) 27% 
(323/1203) 
33% 
(134/408) 
15% 
(149/988) 
21% 
(363/1760) 
29% 
(172/600) 
16% 
(298/1900) 
25% 
(48/195) 
20% 
(177/880) 
20% 
(235/1170) 
22% 
(415/1850) 
Diabetes 17% (78/450) 17% 
(208/1205) 
28% 
(115/408) 
14% 
(142/988) 
25% 
(452/1800) 
32% 
(192/600) 
100% 
(1900/1900) 
100% 
(198/198) 
41% 
(363/880) 
15% 
(184/1184) 
29% 
(554/1905) 
 Insulin 
treated 
NA NA 5% 
(20/408) 
3% 
(28/988) 
10% 
(182/1800) 
3% 
(19/600) 
32% 
(615/1900) 
NA 4% 
(38/880) 
NA 8% 
(147/1905) 
Hypertension 71% (318/450) 45% 
(540/1205) 
62% 
(253/408) 
45% 
(447/988) 
75% 
(1349/1787) 
53% 
(317/600) 
85% 
(1612/1900) 
96% 
(187/195) 
67% 
(591/880) 
66% 
(775/1182) 
74% 
(1404/1892) 
Hypercholesterol
emia 
61% (275/450) 58% 
(694/1201) 
73% 
(298/408) 
52% 
(509/988) 
78% 
(1391/1785) 
41% 
(247/600) 
84% 
(1592/1900) 
58% 
(111/191) 
52% 
(461/880) 
80% 
(946/1183) 
70% 
(1320/1875) 
Peripheral 
vascular disease 
23% (103/450) 5% 
(64/1205) 
0% 
(0/408) 
7% 
(66/988) 
10% 
(177/1800) 
4% 
(22/600) 
10% 
(197/1900) 
14% 
(27/195) 
3% 
(27/880) 
NA 9% 
(181/1896) 
Carotid artery 6% (25/450) NA NA NA 8% NA NA NA NA NA 8% 
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disease (148/1800) (156/1896) 
Previous 
TIA/stroke 
2% (10/450) NA NA 4% 
(37/988) 
8% 
(150/1788) 
NA 3% 
(65/1900) 
10% 
(20/198) 
8% 
(70/879) 
NA 6% 
(119/1903) 
Previous MI 28% (126/450) 43% 
(520/1205) 
47% 
(191/408) 
45% 
(448/988) 
33% 
(585/1780) 
6% 
(33/567) 
26% 
(487/1900) 
42% 
(81/195) 
6% 
(54/880) 
NA 17% 
(330/1888) 
Moderate VEF 
(30-49%) 
20% (88/446) 17% 
(189/1121) 
4%  
(16/408) 
19% 
(149/771) 
17% 
(313/1800) 
5% 
(26/542) 
17% 
(329/1900) 
29% 
(51/177)† 
12%  
(90/744) 
12% 
(120/1020) 
12% 
(215/1804) 
Poor LVEF 
(<30%) 
0% (0/446) 0% (0/1121) 0% 
(0/408) 
1% 
(4/771) 
2% (34/1800) 1% 
(5/542) 
1% 
(27/1900) 
7% 
(12/177) 
1% 
(5/744) 
1% (5/1020) 1% 
(11/1804) 
Unstable angina 
pectoris 
92% (412/450) 36% 
(438/1205) 
0% 
(0/408) 
0% 
(0/988) 
29% 
(513/1800) 
45% 
(272/600) 
31% 
(584/1900) 
NA 44% 
(384/880) 
17% 
(206/1183) 
39% 
(744/1892) 
Number of 
lesions 
2·6 ± 0·6 2·8 ± 1·0 2·8 ± 0·8 2·8 ± 1·1 4·0 ± 1·7 3·0 ± 1·0 NA 3·6 ± 1·5 3·4 ± 1·2 1·7 ± 1·0 NA 
Three-vessel 
disease 
49% (220/450) 33% 
(403/1205) 
58% 
(238/408) 
42% 
(419/988) 
61% 
(1095/1800) 
51% 
(308/600) 
83.4% 
(1573/1887) 
66% 
(120/181) 
77% 
(679/880) 
NA NA 
Left main disease 5% (21/450) 0.1% 
(1/1205) 
0% 
(0/408) 
1% 
(7/988) 
39% 
(705/1800) 
100% 
(600/600) 
0.4% 
(8/1900) 
0% 
(0/198) 
5% 
(47/880) 
100% 
(1184/1184) 
100% 
(1905/1905) 
SYNTAX score NA NA NA NA 28·7 ± 11·4 25·1 ± 10·0 26·2 ± 8·6 NA 24·8 ± 7·7 22·4 ± 7·3 26·5 ± 9·3 
PCI – DES used 0% (0/222) 0% (0/593) 0% 
(0/205) 
0% 
(0/488) 
100% 
(885/885) 
100% 
(276/276) 
100% 
(939/939) 
99%  
(92/93) 
100% 
(413/413) 
100% 
(580/580) 
100% 
(935/935) 
DES type - - - - Paclitaxel Sirolimus Paclitaxel and 
Sirolimus 
Mixed 
paclitaxel, 
sirolimus, 
everolimus, 
zotarolimu
s 
Everolimus Majority 
Biolimus 
Everolimus 
PCI – number of 
stents 
1.4 ± 0.6 NA 1.2 ± 0.9 2.6 ± 1.4 4.6 ± 2.3 2.7 ± 1.4 4.1 ± 1.9 NA 3.4 ± 1.4 2.2 ± 1.2 2.4 ± 1.5 
CABG – LIMA use 95% (198/209) NA 95% 
(188/198) 
93% 
(450/485) 
97% 
(827/854) 
94% 
(233/248) 
94% 
(843/893) 
NA 100% 
(382/382) 
96% 
(545/565) 
99% 
(908/923) 
CABG – BIMA use 0.5% (1/209) NA 32% 
(65/203) 
10% 
(50/485) 
28% 
(236/854) 
NA 12% 
(110/893) 
NA NA 8% (44/549) 29% 
(265/923) 
CABG – off-pump NA NA NA NA 15% 
(128/854) 
63% 
(155/248) 
18% 
(165/893) 
32% 
(26/82) 
66% 
(252/382) 
16% 
(88/564) 
29% 
(271/923) 
Complete 
revascularization 
68% (303/448) 82% 
(992/1205) 
57% 
(224/408) 
70% 
(693/988) 
60% 
(1043/1741) 
69% 
(416/600) 
90% 
(1701/1900) 
NA 61% 
(518/855) 
94% 
(543/577)* 
NA 
Aspirin at 
discharge 
100% (450/450) NA 98% 
(391/397) 
NA 92% 
(1633/1766) 
99% 
(593/600) 
98% 
(1826/1867) 
98% 
(172/176) 
97% 
(852/880) 
93% 
(539/580)* 
98% 
(1823/1867) 
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Thienopyridine 
at discharge 
53% (238/450) NA 48% 
(194/408) 
NA 59% 
(1037/1766) 
94% 
(565/600) 
62% 
(1158/1867) 
55% 
(96/176) 
93% 
(818/880) 
97% 
(566/580)* 
66% 
(1227/1867) 
DAPT at 
discharge 
53% (238/450) NA 47% 
(187/397) 
NA 56% 
(987/1766) 
93% 
(560/600) 
81% 
(1513/1867) 
54% 
(94/176) 
92% 
(806/880)  
92% 
(532/580)* 
65% 
(1204/1867) 
Statin at 
discharge 
NA NA NA NA 80% 
(1425/1766) 
73% 
(431/592) 
88% 
(1566/1770) 
NA 83% 
(733/880) 
NA 95% 
(1740/1840) 
Beta-blocker at 
discharge 
NA NA NA NA 80% 
(1412/1766) 
51% 
(303/592) 
83% 
(1477/1770) 
NA 56% 
(489/880) 
NA 89% 
(1617/1812) 
ACEI or ARB at 
discharge 
NA NA NA NA 59% 
(1042/1766) 
33% 
(198/592) 
75% 
(1334/1770) 
NA 35% 
(307/880) 
NA 50% 
(912/1839) 
Calcium-channel 
blocker at 
discharge 
NA NA NA NA 22% 
(391/1766) 
54% 
(320/592) 
23% 
(405/1770) 
NA 52% 
(459/880) 
NA 7% 
(120/1838) 
Mean follow-up 
(years) 
4·7 ± 1·1 4·8 ± 0·9 4·5 ± 1·3 4·7 ± 0·9 4·4 ± 1·4 4·7 ± 1·0 3·5 ± 1·4 1·4 ± 0·9 4·0 ± 1·3 3·2 ± 1·5 2·6 ± 0·7 
*Data are available only for the PCI group.  
†In the VA CARDS trial, the cut-off for a moderate LVEF was 35-55%. 
Values are present as mean ± SD or n/N (%). NA, not available; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; PCI, 
percutaneous coronary intervention; CABG, coronary artery bypass grafting; BMI, body mass index; TIA, transitory ischemic attack; CVA, cerebrovascular attack; 
MI, myocardial infarction; LVEF, left ventricular ejection fraction; DES, drug-eluting stents; LIMA, left internal mammary artery; BIMA, bilateral internal mammary 
artery; DAPT, dual antiplatelet therapy
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APPENDIX 3. Assessment of risk of bias in individual trials. 
Trial Random 
sequence 
generation 
Allocation 
concealment 
Blinding 
patients and 
personnel 
Blinding 
outcome 
assessment 
Incomplete 
outcome data 
Selective 
reporting 
Other Bias 
ERACI II + - - + + + + 
ARTS ? - - + + + + 
MASS-II ? - - + + + + 
SoS + - - + + + + 
SYNTAX + - - + - + + 
PRECOMBAT + - - + + + - 
FREEDOM + - - + + + + 
VA CARDS + - - + + + - 
BEST + - - + + + - 
NOBLE + - - + + + + 
EXCEL + - - + + + + 
The assessment of “Random sequence generation” was rated “?” for the ARTS and MASS-II trials because it was not specified exactly how randomization took place. 
The assessment of “Allocation concealment” was rated standard as “-“ for all trials because patients had to be informed on the allocated procedure, since these 
trials evaluate interventional procedures. The assessment of “Blinding of patients and personnel” was rated standard as “-“ for all trials because the two 
interventional procedures evaluated are inherently different and patients cannot be blinded. The assessment of “Blinding of outcome assessment” was rated 
standard as “+” for all trials as no bias can be introduced for the endpoint of all-cause mortality, and thus blinding is irrelevant; yet still a clinical events committee 
reviewed all events. The assessment of “Incomplete outcome data” was “-“ for the SYNTAX trial because >10% of patients after CABG were lost to follow-up, while 
this rate was only 3.5% after PCI. The assessment of “Selective reporting” was rated “+” for all trials because all trials reported all-cause mortality. The assessment 
of “Other bias” was rated as “-“ in the RECOMBAT, VA CARDS, and BEST trials because a relatively high percentage (>10%) of patients did not receive the allocated 
treatment because of cross over or no interventional treatment. 
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APPENDIX 4. Information on randomization and actual treatments 
performed. 
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APPENDIX 5. Time-dependent models of PCI versus CABG 
Patient group 
First hazard Second hazard Frailty 
term (𝛝) 
P for 
heterogeneity 
Time 
interval 
HR  
[95% CI] 
Time 
interval 
HR  
[95% CI] 
  
Overall All 0-365 
days 
0∙97 [0∙80-
1∙19] 
365-1825 
days 
1∙38 
[1∙17-
1∙62] 
0∙39 <0∙0001 
 Diabetes 0-280 
days 
1∙05 [0∙78-
1∙42] 
280-1825 
days 
1∙76 
[1∙38-
2∙24] 
0∙11 <0∙0001 
 No diabetes 0-280 
days 
0∙84 [0∙62-
1∙15] 
280-1825 
days 
1∙12 
[0∙90-
1∙37] 
0∙0880 <0∙0001 
 SYNTAX score 
0-22 
0-470 
days 
0∙63 [0∙41-
0∙99] 
470-1825 
days 
1∙40 
[0∙97-
2∙01] 
0∙0454 0∙0094 
 SYNTAX score 
23-32 
0-470 
days 
1∙03 [0∙72-
1∙46] 
280-1825 
days 
1∙36 
[0∙99-
1.87] 
0∙0657 0∙0031 
 SYNTAX score 
≥33 
0-470 
days 
1∙83 [1∙18-
2∙82] 
280-1825 
days 
1∙34 
[0∙93-
1∙95] 
0∙0191 0∙0602 
 Bare-metal 
stent 
0-730 
days 
0∙90 [0∙64-
1∙27] 
730-1825 
days 
1∙22 
[0∙86-
1∙73] 
0∙16 <0∙0001 
 Drug-eluting 
stent 
0-500 
days 
1∙08 [0∙87-
1∙34] 
500-1825 
days 
1∙45 
[1∙18-
1∙77] 
0∙36 <0∙0001 
 First-
generation 
drug-eluting 
stent 
0-730 
days 
1∙12 [0∙87-
1∙45] 
730-1825 
days 
1∙31 
[1∙01-
1∙73] 
0∙23 <0∙0001 
 Newer-
generation 
drug-eluting 
stent 
0-180 
days 
0∙68 [0∙43-
1∙10] 
180-1825 
days 
1∙65 
[1∙21-
2∙25] 
0∙13 0∙0020 
MVD All 0-280 
days 
0∙99 [0∙76-
1∙29] 
280-1825 
days 
1∙46 
[1∙20-
1∙77] 
0∙40 <0∙0001 
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 Diabetes 0-280 
days 
1∙11 [0∙78-
1∙58] 
280-1825 
days 
1∙77 
[1∙34-
2∙34] 
0∙16 <0∙0001 
 No diabetes 0-370 
days 
0∙94 [0∙64-
1∙40] 
370-1825 
days 
1∙16 
[0∙88-
1∙53] 
0∙090 <0∙0001 
 SYNTAX score 
0-22 
0-600 
days 
0∙65 [0∙37-
1∙14] 
600-1825 
days 
1∙78 
[1∙05-
3∙01] 
0∙0935 0∙0140 
 SYNTAX score 
23-32 
0-600 
days 
1∙43 [0∙91-
2∙24] 
600-1825 
days 
1∙60 
[1∙00-
2∙55] 
0∙0720 0∙0065 
 SYNTAX score 
≥33 
0-600 
days 
1∙72 [0∙97-
3∙04] 
600-1825 
days 
1∙70 
[0∙95-
3∙01] 
0∙0252 0∙0505 
LM All 0-730 
days 
1∙09 [0∙82-
1∙44] 
730-1825 
days 
1∙06 
[0∙76-
1∙48] 
0∙0845 <0∙0001 
 Diabetes 0-730 
days 
1∙22 [0∙79-
1∙86] 
730-1825 
days 
1∙70 
[0∙86-
3∙35] 
0∙0543 0∙0172 
 No diabetes 0-730 
days 
0∙98 [0∙67-
1∙43] 
730-1825 
days 
0∙90 
[0∙61-
1∙32] 
0∙0604 0∙0027 
 SYNTAX score 
0-22 
0-570 
days 
0∙68 [0∙37-
1∙25] 
570-1825 
days 
1∙12 
[0∙64-
1∙94] 
<0∙0001 0∙0001 
 SYNTAX score 
23-32 
0-570 
days 
0∙79 [0∙50-
1∙25] 
570-1825 
days 
1∙13 
[0∙70-
1∙90] 
0∙0626 0∙0093 
 SYNTAX score 
≥33 
0-570 
days 
1∙70 [0∙96-
3∙02] 
570-1825 
days 
1∙16 
[0∙67-
1∙99] 
0∙0222 0∙0647 
DM SYNTAX score 
0-22 
0-730 
days 
0∙60 [0∙36-
0∙99] 
730-1825 
days 
2∙70 
[1∙40-
5∙21] 
<0∙0001 0∙0001 
 SYNTAX score 
23-32 
0-730 
days 
1∙30 [0∙90-
1∙89] 
730-1825 
days 
1∙35 
[0∙78-
2∙34] 
0∙0159 0∙0713 
 SYNTAX score 
≥33 
0-730 
days 
1∙78 [1∙06-
2∙97] 
730-1825 
days 
1∙75 
[0∙92-
3∙34] 
<0∙0001 0∙0001 
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NO DM SYNTAX score 
0-22 
0-730 
days 
0∙91 [0∙52-
1∙59] 
730-1825 
days 
0∙99 
[0∙55-
1∙79] 
<0∙0001 0∙0193 
 SYNTAX score 
23-32 
0-730 
days 
0∙90 [0∙54-
1∙48] 
730-1825 
days 
1∙19 
[0∙70-
2∙03] 
0∙0807 0∙0096 
 SYNTAX score 
≥33 
0-730 
days 
1∙80 [1∙00-
3∙23] 
730-1825 
days 
1∙00 
[0∙58-
1∙73] 
0∙0089 0∙0884 
Results of time-dependent models provide a hazard ratio for a first time interval and a second 
interval with the duration of this interval being dependent on when the hazard changes, which 
can be different according to the patient cohort. CI, confidence interval; DM, diabetes mellitus; 
HR, hazard ratio.
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APPENDIX 6. Five-year outcomes within groups with and without diabetes according to SYNTAX score tertiles. 
 Diabetes No diabetes 
 PCI 
(n=1819) 
CABG 
(n=1782) 
HR [95% CI] 
P-value 
P for 
interaction  
PCI 
(n=2262) 
CABG 
(n=2275) 
HR [95% CI] 
P-value 
P for 
interaction  
SYNTAX score 0-22 13·0% 
(58/622) 
9·8% 
(53/655) 
1·09 [0·75-1·58] 
P=0·66 
Pint=0·25 6·6% 
(47/911) 
7·0% 
(47/930) 
0·95 [0·63-1·42] 
P=0·80 
Pint=0·66 
SYNTAX score 23-32 15·1% 
(101/814) 
12·5% 
(67/723) 
1·32 [0·97-1·79] 
P=0·0817 
9·9% 
(62/863) 
9·4% 
(55/822) 
1·03 [0·71-1·48] 
P=0·88 
SYNTAX score ≥33 20·0% 
(63/383) 
12·3% 
(38/404) 
1·77 [1·18-2·64] 
P=0·0056 
13·6% 
(54/488) 
11·1% 
(45/523) 
1·32 [0·89-1·96] 
P=0·16 
Kaplan-Meier estimates are from the overall pooled patient population. Hazard ratios (HRs) with confidence intervals (CIs) are derived from Cox proportional 
hazards random-effects models stratified by trial.
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